Firalis launches a range of CE marked immunoassays for the titration of cardiovascular markers
Firalis SAS, a biomarker service provider & product developer, is pleased to announce the release of its new range of immunoassays for Prx2, VEGFb and PGF. Three markers are known to vary in various conditions of the cardiovascular system.
> The Enzyme immunoassays for the quantitative
determination of Peroxiredoxin 2 (Prx-2*)
> Placental Growth Factor (PGF**)
> Vascular Endothelium Growth Factor b (VEGFb***)
For more information, please contact email@example.com.
The Immunoassays are based on proprietary monoclonal antibodies and constitute the first references of a range of assays to be progressively released over the next months.
The release of these products allows Firalis to capitalize on its IP in the field of cardiovascular diseases. VEGFb and PGF have been shown to be useful for the prediction of outcome in high cardiac risk patients by being predictive for the onset of heart failure. This application is protected by a series of granted patents controlled by Firalis.
* * *
* Prx2 belongs to a family of anti-oxidant enzymes. The enzymes exert an antioxidative role through their peroxidase activity, reducing and detoxifying hydrogen peroxide, peroxynitrite and hydroxyperoxidases. The availability of Prx was shown to correlate with the extent of atherosclerotic lesions in animal models.
** PGF is a protein belonging to the VEGF sub-familly and was initially isolated from placenta where it plays a key role in angiogenesis. Recently, PGF has been shown to be upregulated in atherosclerotic lesions where it promotes smooth muscle cell proliferation and recruitment of inflammatory cells, therefore promoting plaque instability. Clinical studies have shown a strong association between high serum PGF levels and cardiovascular events in high risk populations.
*** VEGFb is one of 5 mammalian VEGF family members. While the roles of various VEGF family members have been known for a relatively long time; that of VEGFb remained an enigma until recently. VEGFb has been held uniquely responsible for angiogenesis in the myocardium. Taken together with the alteration of VEGFb levels in cardiac pathologies, this discovery turned VEGFb into a promising emerging marker in pathologies related to myocardial remodeling.
* * *
Firalis SAS is a privately owned life sciences company, creating novel values via biomarker discovery, development and regulatory qualifications; to establish an internal portfolio of biomarker-based diagnostic methods and to provide customized biomarker solutions. Firalis is active in the field of drug safety, cardiovascular, inflammatory and autoimmune diseases. The company has been awarded with several national and international prizes for its innovative approaches.